drugset / Trial / NCT07114640
The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions: Which medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?
Timeline
- Start
- 2025-08-07
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | 25 mg | — |
| Comparator | Oxybutynin | Small molecule | 5 mg | — |
| Comparator | Solifenacin | Small molecule | 5 mg | — |
| Comparator | Tolterodine | Small molecule | 4 mg | — |